

Borough Park
1428 36th Street
Suite 107
Brooklyn, NY 11218

Crown Heights
555 Lefferts Avenue
Brooklyn, NY 11225

Manhattan
57W 57 Street
Suite 601
New York, NY 10019

Manhasset
333 East Shore Road
Suite 201
Manhasset, NY 11030

Rockville Centre
165 North Village Avenue
Suite 133
Rockville Center, NY 11570

Elmsford/Tarrytown
555 Taxter Road
3rd Floor
Elmsford, NY 10523

NYC Central Park West
115 Central Park West
Suite 15
New York, NY 10023

Woodbury
75 Froehlich Farm
Woodbury, NY 11797

Staten Island
27 New Dorp Lane
Staten Island, NY 10306



Office: 212-803-3339 Fax: 646-768-8600



Manhattan
225 E 70th Street
Suite 1E
New York, NY 10021

Queens
64-05 Yellowstone Blvd
CF104
Forest Hills, NY 11375

Manhattan
225 East 70th Street
New York, NY 10021

Holbrook/Ronkonkoma
233 Union Ave
Suite 207
Holbrook, NY 11741

Scarsdale
495 Central Park Avenue
Suite 205
Scarsdale, NY 10583

5 Towns
141 Washington Avenue
Cedarhurst, NY 11559

Long Beach
917 Beech Street
Long Beach, NY 11561

Riverhead
1228 E Main Street
Suite A
Riverhead, NY 11901

Bronx
226 West 238th Street
Bronx, NY 10463

OMVOH (mirikizumab-mrkz)

Provider Order Form

Date: _____

PATIENT INFORMATION

Name:	DOB:	SEX: M <input type="checkbox"/> F <input type="checkbox"/>
ICD-10 code (required):	ICD-10 description:	
<input type="checkbox"/> NKDA Allergies:	Weight lbs/kg:	

REFERRAL STATUS

New Referral Referral Renewal Medication/Order Change Benefits Verification Only Discontinuation Order

PHYSICIAN INFORMATION

Referral Coordinator Name:	Referral Coordinator Email:		
Ordering Provider:	Provider NPI:		
Referring Practice Name:	Phone:	Fax:	
Practice Address:	City:	State:	Zip Code:

INDICATIONS AND USAGE

OMVOHTM is an interleukin-23 antagonist indicated for the treatment of moderately to severely active ulcerative colitis in adults (1)

DOSAGE AND ADMINISTRATION

Prior to Treatment Initiation

- Evaluate patients for tuberculosis (TB) infection. (2.1, 5.3)
- Obtain liver enzymes and bilirubin levels. (2.1, 5.4)
- Complete all age-appropriate vaccinations according to current

Recommended Dosage

- The recommended induction dosage is 300 mg administered by intravenous infusion over at least 30 minutes at Weeks 0, 4, and 8. (2.2)
- The recommended maintenance dosage is 200 mg administered by subcutaneous injection (given as two consecutive injections of 100 mg each) at Week 12, and every 4 weeks thereafter. (2.2)

Preparation and Administration

- See the full prescribing information for preparation, administration and storage information for intravenous infusion and subcutaneous injection. (2.3, 2.4)

DOSAGE FORMS AND STRENGTH

Intravenous Infusion (3)

- Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial
- Subcutaneous Injection (3):
- Injection: 100 mg/mL solution in a single-dose pre-filled pen

CONTRAINDICATIONS

History of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients. (4, 5.1).

WARNINGS AND PRECAUTIONS

- Hypersensitivity Reactions:** Serious hypersensitivity reactions, including anaphylaxis and infusion-related reactions, have been reported. If a severe hypersensitivity reaction occurs, discontinue and initiate appropriate treatment. (5.1)
- Infections:** OMVOH may increase the risk of infection. Do not initiate treatment with OMVOH in patients with a clinically important active infection until the infection resolves or is adequately treated. If a serious infection develops, do not administer OMVOH until the infection resolves. (5.2)
- Tuberculosis:** Do not administer OMVOH to patients with active TB infection. Monitor patients receiving OMVOH for signs and symptoms of active TB during and after treatment. (5.3)
- Hepatotoxicity:** Drug-induced liver injury has been reported. Monitor liver enzymes and bilirubin levels at baseline and for at

least 24 weeks of treatment and thereafter according to routine patient management. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. (5.4)

- Immunizations:** Avoid use of live vaccines. (5.5)

ADVERSE REACTIONS

Most common adverse reactions ($\geq 2\%$) are:

- Induction: upper respiratory tract infections and arthralgia. (6.1)
- Maintenance: upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection. (6.1)

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Evaluations and Immunizations Prior to Treatment Initiation

2.2 Recommended Dosage

2.3 Preparation and Administration of OMVOH for Intravenous Infusion

2.4 Preparation and Administration of OMVOH for Subcutaneous Injection

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

5.2 Infections

5.3 Tuberculosis

5.4 Hepatotoxicity

5.5 Immunizations

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

12.6 Immunogenicity

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.